AR076514A1 - Composicion farmaceutica para la administracion oral de un promotor de apoptosis. uso. - Google Patents

Composicion farmaceutica para la administracion oral de un promotor de apoptosis. uso.

Info

Publication number
AR076514A1
AR076514A1 ARP100101474A ARP100101474A AR076514A1 AR 076514 A1 AR076514 A1 AR 076514A1 AR P100101474 A ARP100101474 A AR P100101474A AR P100101474 A ARP100101474 A AR P100101474A AR 076514 A1 AR076514 A1 AR 076514A1
Authority
AR
Argentina
Prior art keywords
composition
active ingredient
pharmaceutically acceptable
formula
disease
Prior art date
Application number
ARP100101474A
Other languages
English (en)
Inventor
Yeshwant Sanzgiri
Yi Shi
Ping Tong
Huailiang Wu
Geoff Zhang
Deliang Zhou
Jonathan M Miller
Kennan Marsh
Anthony R Haight
Katherine Heemstra
Rajeev Gokhale
Nathaniel Catron
Michael Fickes
David Hill
Yanxia Li
Martin Knobloch
Kostelac Drazen Dr
Christina Fischer
Justin S Lafountaine
Bernd De Liepold
Claudia Dr Packhaeuser
Norbert Steiger
Original Assignee
Abbott Lab
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Abbott Gmbh & Co Kg filed Critical Abbott Lab
Publication of AR076514A1 publication Critical patent/AR076514A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Una composicion farmacéutica de administracion oral caracterizada porque comprende como unico o primer ingrediente activo un compuesto de la formula (1) donde X3 es cloro o fluoro; y (1) X4 es azepan-1-ilo, morfolin-4-ilo, 1,4-oxazepan-4-ilo, pirrolidin-1-ilo, -N(CH3)2, -N(CH3)(CH(CH3)2), 7-azabiciclo[2,2,1]heptan-7-ilo o 2-oxa-5-azabiciclo[2,2,1] hept-5-ilo; y R0 es como en formula (2) donde X5 es -CH2-, -C(CH3)2- o -CH2CH2-; X6 y X7 son ambos H o metilo; y X8 es fluoro, cloro, bromo o iodo; o (2) X4 es azepan-1-ilo, morfolin-4-ilo, pirrolidin-1-ilo, N(CH3)(CH(CH3)2) o 7-azabiciclo[2,2,1]heptan-7-ilo; y R0 es como en formula (3) donde X6, X7 y X8 son como se describio con anterioridad; o (3) X4 es morfolin-4-il o -N(CH3)2; y R0 es como en formula (4) donde X8 es como se describio con anterioridad; o una sal farmacéuticamente aceptable de éste, en una cantidad, expresada en equivalentes de la base libre, de al menos aproximadamente 2,5% en peso de la composicion, disperso en un vehículo farmacéuticamente aceptable; donde dicho ingrediente activo toma una forma en estado solido, y/o donde la composicion también comprende un antioxidante farmacéuticamente aceptable que contiene chalcogenos pesados (HCA) dispersado en el vehículo, en una cantidad eficaz para inhibir la oxidacion del ingrediente activo en uno de sus enlaces tioéter. Reivindicacion 4: La composicion de la reivindicacion 3, caracterizada porque el ingrediente activo comprende la base libre de ABT-263 o la sal de bis-clorhidrato de ABT-263 (ABT-263 bis-HCI). Reivindicacion 10: La composicion de cualquiera de las reivindicaciones 1-9, caracterizada porque el vehículo es líquido y comprende dicho ingrediente activo y un HCA farmacéuticamente aceptable en una cantidad eficaz como antioxidante en solucion o en suspension. Reivindicacion 12: La composicion de cualquiera de las reivindicaciones 1-11, caracterizada porque dicho ingrediente activo se halla en una forma amorfa o cristalina que tiene partículas con un tamano D90 no mayor que aproximadamente 30 mm. Reivindicacion 13: Uso de una composicion de cualquiera de las reivindicaciones 1-12, caracterizado porque es para tratar una enfermedad caracterizada por una disfuncion apoptotica y/o por la sobreexpresion de una proteína antiapoptotica de la familia Bcl-2, mediante la administracion de la composicion en una dosis diaria eficaz para el uso terapéutico a un sujeto que tiene la enfermedad. Reivindicacion 14: El uso de la reivindicacion 13, caracterizado porque la enfermedad es una enfermedad neoplástica.
ARP100101474A 2009-04-30 2010-04-30 Composicion farmaceutica para la administracion oral de un promotor de apoptosis. uso. AR076514A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17429909P 2009-04-30 2009-04-30
US17431809P 2009-04-30 2009-04-30
US18510509P 2009-06-08 2009-06-08
US18513009P 2009-06-08 2009-06-08
US21828109P 2009-06-18 2009-06-18
US28925409P 2009-12-22 2009-12-22
US28928909P 2009-12-22 2009-12-22

Publications (1)

Publication Number Publication Date
AR076514A1 true AR076514A1 (es) 2011-06-15

Family

ID=42651489

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101474A AR076514A1 (es) 2009-04-30 2010-04-30 Composicion farmaceutica para la administracion oral de un promotor de apoptosis. uso.

Country Status (5)

Country Link
US (1) US20100297194A1 (es)
AR (1) AR076514A1 (es)
TW (1) TW201041880A (es)
UY (1) UY32602A (es)
WO (1) WO2010127198A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
NZ598461A (en) 2009-09-20 2013-12-20 Abbvie Inc Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
CA2780177A1 (en) * 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
PL2575784T3 (pl) 2010-06-02 2019-03-29 Astellas Deutschland Gmbh Doustne postaci dawkowania bendamustyny
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2811805A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
KR101923364B1 (ko) 2010-11-23 2018-11-30 애브비 인코포레이티드 아폽토시스­유도제의 염 및 결정형
DK2642999T3 (en) 2010-11-23 2017-01-09 Abbvie Ireland Unlimited Co METHODS OF TREATMENT FOR USING selectivity-VE BCL-2 INHIBITORS
DE102011010437A1 (de) * 2011-02-04 2012-08-09 J. Rettenmaier & Söhne Gmbh + Co. Kg Tablettierhilfsmittel
WO2013098577A1 (en) * 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of bosentan
ES2687705T3 (es) 2012-07-19 2018-10-26 Fujifilm Corporation Composición líquida que contiene un principio activo a base de taxano, proceso de producción de la misma y preparación medicinal líquida
EP3725778B1 (en) 2012-09-11 2021-08-18 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2744198T3 (es) * 2013-04-17 2020-02-24 Signal Pharm Llc Formulaciones farmacéuticas, procesos, formas sólidas y procedimientos de uso relacionados con 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3, 4 dihidropirazino[2,3-b]pirazin-2(1H)-ona
US10201549B2 (en) * 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions
WO2016011535A1 (en) 2014-07-25 2016-01-28 Laurent Pharmaceuticals Solid oral formulation of fenretinide
US10406127B2 (en) * 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
EP3328214B1 (en) 2015-07-29 2020-04-01 Abbott Laboratories Nutritional products having improved lipophilic solubility and bioavailability in an easily mixable form
US10285987B2 (en) 2017-04-28 2019-05-14 Amplipharm Pharmaceuticals, LLC Device and kit for dosing and dispensing non-liquid medicine
US9949967B2 (en) 2016-04-28 2018-04-24 Amplipharm Pharmaceuticals, LLC Temozolomide powder formulation
CA3062764A1 (en) * 2016-04-28 2017-11-02 Amplipharm Pharmaceuticals, LLC Temozolomide powder formulation
US11331316B2 (en) * 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
EP4051286A1 (en) * 2019-10-29 2022-09-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating uveal melanoma
US11285159B2 (en) 2019-11-05 2022-03-29 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax
IL295803A (en) * 2020-02-24 2022-10-01 Newave Pharmaceutical Inc Hot melt solid dispersions containing a bcl2 inhibitor
US11684582B2 (en) * 2021-03-31 2023-06-27 Delta-Fly Pharma, Inc. Method for stabilizing humidity-sensitive pharmaceutical substance and stabilized preparation thereof
US11878025B2 (en) 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
AU2006297853B2 (en) * 2005-05-12 2010-08-19 AbbVie Global Enterprises Ltd. Apoptosis promoters
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
CN101939008A (zh) * 2007-12-06 2011-01-05 雅培制药有限公司 用于治疗癌症的abt-263经口组合物

Also Published As

Publication number Publication date
TW201041880A (en) 2010-12-01
US20100297194A1 (en) 2010-11-25
UY32602A (es) 2010-09-30
WO2010127198A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
AR076514A1 (es) Composicion farmaceutica para la administracion oral de un promotor de apoptosis. uso.
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
CU20120069A7 (es) Derivados de la cromenona con actividad anti-tumoral
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
EA200901277A1 (ru) Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
ECSP19020742A (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
ECSP12011703A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
BR112015014433A2 (pt) compostos tricíclicos
UY35211A (es) Compuestos tricíclicos
CR11734A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
CO6410283A2 (es) Métodos para administrar (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a través de la mucosa oral, la mucosa nasal o la piel, y sus compoisiciones farmacéuticas
PE20151607A1 (es) Formulaciones de compuestos organicos
AR076512A1 (es) Formulacion en lipidos de un promotor de la apoptosis
BRPI1011851A2 (pt) Composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, epara tratar uma doença
RU2013157398A (ru) Композиция

Legal Events

Date Code Title Description
FA Abandonment or withdrawal